According to a report compiled by Fortune, total income of Aurobindo Pharma, has surged 31.9 per cent Y-o-Y to Rs 15.7 billion during Q4FY13, led by US formulations business. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin was lower at 15.3 per cent, improved by 350 bps Y-o-Y.
Adjusted PAT increased by 137.3 per cent Y-o-Y. There was a sequential increase in depreciation and tax rate. US formulations sales growth was staggering at 61.5 per cent Y-o-Y in Q4FY13, led by series of ANDA launches and favourable exchange rate during FY13.
The API segment posted 16.9 per cent growth Y-o-Y in Q4FY13 led by Ceph APIs. API segment posted growth of 22.9 per cent in FY13 which is the highest in the last six years. Growth in FY13 was primarily driven by SSP and Cephs oral APIs which grew by 26.2 per cent and 30.8 per cent as they were able to take price increase in certain products.
EP News Bureau – Mumbai